AC
ACRV.US Acrivon Therapeutics, Inc. Common Stock
- Market cap
- USD 62.6M
- P/E
- -
- P/B
- 0.78x
- ROE
- -85.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is ACRV.US undervalued?
Graham numberThe Graham number of Acrivon Therapeutics, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Acrivon Therapeutics, Inc. Common Stock fundamental analysis
No fundamental analysis for Acrivon Therapeutics, Inc. Common Stock yet.
Acrivon Therapeutics, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Acrivon Therapeutics, Inc. Common Stock
Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients…
Full company profileAcrivon Therapeutics, Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Acrivon Therapeutics, Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -13.0K | -832K | -1.10M | -536K | -1.01M | -1.36M | - |
| Operating Income | -3.17M | -16.2M | -32.7M | -67.2M | -89.2M | -84.1M | -77.1M |
| EBITDA | -5.29M | -16.2M | -32.3M | -59.9M | -79.6M | -76.5M | -72.4M |
| Net Income | -5.31M | -16.2M | -29.7M | -60.4M | -80.6M | -77.9M | -74.0M |
| EPS | -0.41 | -1.26 | -1.35 | -2.74 | -2.10 | -2.02 | -1.77 |
| Balance Sheet | |||||||
| Total Assets | 2.19M | 107M | 181M | 138M | 197M | 130M | 99.1M |
| Total Liabilities | 10.6M | 130M | 10.8M | 17.1M | 19.8M | 17.2M | 12.4M |
| Shareholders' Equity | -8.41M | -23.8M | 170M | 121M | 177M | 113M | 86.7M |
| Cash & Short-term Investments | 1.58M | 99.6M | 128M | 127M | 179M | 119M | 90.0M |
| Total Debt | 58.0K | 5.63M | 4.96M | 4.64M | 3.65M | 2.71M | 2.12M |
| Cash Flow | |||||||
| Operating Cash Flow | -2.80M | -14.0M | -30.1M | -42.6M | -65.7M | -63.7M | -70.8M |
| Capital Expenditure | 15.0K | 238K | 2.17M | 1.29M | 2.77M | 1.67M | 202K |
| Free Cash Flow | -2.82M | -14.2M | -32.3M | -43.9M | -68.4M | -65.3M | -71.0M |
| Ratios | |||||||
| ROE | - | - | -17.4% | -49.8% | -45.6% | -69.2% | -85.4% |
| ROA | -242.8% | -15.2% | -16.4% | -43.7% | -41.0% | -60.1% | -74.7% |
| Debt to Equity | - | - | 0.03x | 0.04x | 0.02x | 0.02x | 0.02x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Acrivon Therapeutics, Inc. Common Stock dividends
Acrivon Therapeutics, Inc. Common Stock has not paid dividends in the last 6 fiscal years.
Who owns Acrivon Therapeutics, Inc. Common Stock
- Insiders 15.40%
- Institutions 50.76%
- Public & others 33.85%
- Shares outstanding 42.9M
- Free float 25.8M
Top funds holding ACRV.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 707K | 1.65% | +29.51% | Sep 2026 |
| Bridgeway Ultra-Small Company | 316K | 0.74% | +172.41% | Jun 2026 |
| Fidelity Extended Market Index | 155K | 0.36% | -0.38% | Sep 2026 |
| A4Investments SICAV SIF ACCI IlanaA2EURH | 130K | 0.30% | 0.00% | Oct 2026 |
| Vifag 2002 SICAV | 67.5K | 0.16% | 0.00% | Sep 2026 |
| iShares Micro-Cap ETF | 59.5K | 0.14% | 0.00% | Oct 2026 |
| EA Bridgeway Ultra-Small Company Mkt ETF | 56.4K | 0.13% | 0.00% | Oct 2026 |
| Fidelity Series Total Market Index | 42.5K | 0.10% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 39.5K | 0.09% | 0.00% | Sep 2026 |
| Nationwide Bailard Sm Cp Val M | 29.8K | 0.07% | 0.00% | Jan 2026 |
| Vanguard Balanced Index Inv | 16.9K | 0.04% | 0.00% | Sep 2026 |
| Vanguard U.S. Eq Idx £ Acc | 8.57K | 0.02% | -63.64% | Sep 2026 |
| DFA U.S. Vector Equity I | 7.06K | 0.02% | 0.00% | Sep 2026 |
| Dimensional Gl Cor Eq LC ESG Sc USD A | 6.10K | 0.01% | -0.41% | Sep 2026 |
| Dimensional Global Core Equity USD Acc | 5.47K | 0.01% | -0.29% | Sep 2026 |
| 1290 VT Micro Cap K | 4.94K | 0.01% | 0.00% | Sep 2026 |
| DFA US Social Core Equity 2 Portfolio | 4.64K | 0.01% | 0.00% | Sep 2026 |
| Dimensional World Allc 60/40 GBP Acc | 1.80K | 0.00% | 0.00% | Sep 2026 |
| Dimensional International Core Eq Acc | 1.70K | 0.00% | 0.00% | Sep 2026 |
| Global Core Equity UCITS ETF USD Acc | 427.00 | 0.00% | 0.00% | Oct 2026 |
Top institutions holding ACRV.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| RA Capital Management, LLC | 12.2M | 28.54% | +46.63% | Jun 2026 |
| Sands Capital Ventures, LLC | 2.29M | 5.34% | +7.85% | Jun 2026 |
| Acadian Asset Management LLC | 1.17M | 2.72% | +37.73% | Jun 2026 |
| Vanguard Capital Management, LLC | 952K | 2.22% | +31.85% | Jun 2026 |
| Wellington Management Company LLP | 888K | 2.07% | 0.00% | Jun 2026 |
| Renaissance Technologies Corp | 759K | 1.77% | +0.06% | Jun 2026 |
| Two Sigma Investments LLC | 641K | 1.50% | +64.74% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 532K | 1.24% | -5.10% | Jun 2026 |
| Bridgeway Capital Management, LLC | 379K | 0.88% | +138.45% | Jun 2026 |
| Geode Capital Management, LLC | 265K | 0.62% | +12.20% | Jun 2026 |
| BlackRock Inc | 239K | 0.56% | +14.44% | Jun 2026 |
| GSA Capital Partners LLP | 200K | 0.47% | +7.34% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 184K | 0.43% | +71.24% | Jun 2026 |
| XTX Topco Ltd | 178K | 0.42% | +166.50% | Jun 2026 |
| Jane Street Group LLC | 74.6K | 0.17% | -68.86% | Jun 2026 |
| Northern Trust Corp | 67.2K | 0.16% | +37.42% | Jun 2026 |
| State Street Corp | 67.1K | 0.16% | 0.00% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 46.2K | 0.11% | +57.47% | Sep 2026 |
| UBS Group AG | 43.9K | 0.10% | +26.61% | Jun 2026 |
| Citadel Advisors Llc | 41.3K | 0.10% | 0.00% | Jun 2026 |
Acrivon Therapeutics, Inc. Common Stock company profile
- Company name
- Acrivon Therapeutics, Inc. Common Stock
- Ticker
- ACRV.US
- Exchange
- USA Stocks
- Listed since
- Nov 15, 2022
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 74
- Fiscal year end
- December
- Address
- 480 Arsenal Way, Watertown, MA, United States, 02472
- Phone
- 617 207 8979
- Website
- acrivon.com
About Acrivon Therapeutics, Inc. Common Stock
Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer. The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program. The company was incorporated in 2018 and is based in Watertown, Massachusetts.
Acrivon Therapeutics, Inc. Common Stock management
10- Dr. Peter Blume-Jensen M.D., Ph.D.Co-Founder, Chairman of the Board, CEO, President & Acting Chief Scientific Officer · born 1963
- Ms. Kristina Masson M.B.A., Ph.D.Co-Founder, Executive VP of Business Operations, Site Head, Treasurer & Director · born 1980
- Dr. Eric J. Devroe Ph.D.Chief Operating Officer · born 1979
- Dr. Adam D. Levy M.B.A., Ph.D.CFO & Principal Financial Officer · born 1966
- Ms. Katharine Peterson CPAVice President of Finance & Accounting
- Mr. Bruce CloseVice President of Quality & Compliance
- Ms. Mary-Alice Miller J.D.Chief Legal Officer & Corporate Secretary · born 1974
- Dr. Erick Gamelin M.D., Ph.D.Chief Development Officer · born 1958
- Dr. Jesper V. Olsen Ph.D.Academic Co-Founder, Head of Phosphoproteomics & Member of Scientific Advisory Board
- Mr. Joon Jung Ph.D.VP & Head of Data Science